What is the story about: Pharma stock soars 150% on injectables deal with Wegovy maker Novo?

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

How do left, center, and right outlets frame this story?

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

Where can I read the original reporting?

Kodawire links to 1 source for this story.

Bias Comparison — Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Media Spectrum

Total: 1 source•Published: 30m ago•Last Updated: 5m ago

0%0%100%

LeftCenterRight

Left-leaning

Coverage Gap

Unreported by left-leaning outlets. Coverage is currently concentrated on other perspectives.

0 sources

Center

Coverage Gap

Unreported by center outlets. Coverage is currently concentrated on other perspectives.

0 sources

Right-leaning

100% of coverage

UT

US Top News and Analysis (US)

Pharma stock soars 150% on injectables deal with Wegovy maker Novo

View all 1 sources

Bias & Framing Analysis

Top Framing Differences

Left: Coverage gap: Currently unaddressed by verified outlets on this side of the spectrum.
Center: Coverage gap: Currently unaddressed by verified outlets on this side of the spectrum.
Right: Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

Overall Tone

Right-leaning

Coverage Blindspots

Left

Coverage blindspot: Reporting on this development is currently concentrated in other segments of the media landscape.

Right

Right-leaning desks have 1 source on "Pharma stock soars 150% on injectables deal with Wegovy maker Novo"; additional angles may appear as coverage expands.

Credibility & Editorial Standards

Story FramingRight

Evaluated across 1 reporting source (0% Left · 0% Center · 100% Right)

L 0%C 0%R 100%

Outlet ConsensusRight

Historical editorial baseline for US Top News and Analysis (US)

BusinessRight

Politics & GovernanceRight

Credibility ScoreHigh Credibility

89/ 100

Multi-factor accuracy index for US Top News and Analysis (US) and related desks based on verifiable sourcing and editorial standards.

Factuality: High 100%

Ownership: US Top News and Analysis (US) (Corporate)

Timeline of this story

7m agoUS Top News and Analysis (US): Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant

Historical Context

2024 — Global Monetary Easing

Central banks pivot from multi-decade rate hikes to targeted easing cycles.

2023 — Regional Bank Liquidity Crisis

Rapid digital runs prompt emergency deposit backstops and tighter capital oversight.

2022 — Commodity Shocks & Reshoring

Supply disruption accelerates corporate nearshoring and friend-shoring investments.

Posts on X

Public conversation related to this story

Kentucky football has had two quarters of “bad” football this season. Other than those 30 minutes of disappointment, the Wildcats have been absolutely spectacular. They came out in their season opener against Youngstown State and handled business, as they should. Then, they took a halftime lead and physically dominated No. 10 Alabama before those 30 […]

L 0%C 0%R 100%

1 sources • 1

Can you spend your way out of loneliness?

Multiple outlets • 48m ago

Over the years, Julianne Holt-Lunstad has fielded many requests from startups looking for her help. These entrepreneurs came to the Brigham Young University professor with the well-meaning goal of “solving” loneliness; they believed their app or company could help consumers build genuine connections, and wanted Holt-Lunstad’s opinion on this feature or that business tactic. Across the pond, University College London professor Noreena Hertz was getting the same calls. They wanted her to join thei

L 100%C 0%R 0%

1 sources • 1

Bernstein upgrades 3M stock rating on R&D transformation progress

Multiple outlets • 49m ago

Bernstein upgrades 3M stock rating on R&D transformation progress

L 0%C 100%R 0%

1 sources • 1

TD Cowen raises Charles River Labs stock price target on growth outlook

Multiple outlets • 49m ago

TD Cowen raises Charles River Labs stock price target on growth outlook

L 0%C 100%R 0%

1 sources • 1

UBS upgrades Glencore as commodity gains boost earnings outlook

Multiple outlets • 51m ago

UBS upgrades Glencore as commodity gains boost earnings outlook

L 0%C 100%R 0%

1 sources • 1

Wells Fargo initiates Emerson stock with overweight rating on growth

Multiple outlets • 55m ago

Wells Fargo initiates Emerson stock with overweight rating on growth

L 0%C 100%R 0%

1 sources • 1

Wells Fargo initiates Trane Technologies stock at Overweight on data center growth

Multiple outlets • 55m ago

Wells Fargo initiates Trane Technologies stock at Overweight on data center growth

L 0%C 100%R 0%

1 sources • 1

Reader Discussion

Loading comments…

Pharma stock soars 150% on injectables deal with Wegovy maker Novo